Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF.

Circulation. 1999 Dec 7;100(23):2312-8.

PMID:
10587334
[PubMed - indexed for MEDLINE]
Free Article
2.

[Clinical study of the month. The ATLAS study].

Kulbertus H.

Rev Med Liege. 1999 Dec;54(12):952-4. French.

PMID:
10686803
[PubMed - indexed for MEDLINE]
3.

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.

Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Rydén L.

Arch Intern Med. 2001 Jan 22;161(2):165-71.

PMID:
11176729
[PubMed - indexed for MEDLINE]
5.

High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.

Schwartz JS, Wang YR, Cleland JG, Gao L, Weiner M, Poole-Wilson PA; ATLAS Study Group.

Am J Manag Care. 2003 Jun;9(6):417-24.

PMID:
12816171
[PubMed - indexed for MEDLINE]
Free Article
6.

Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure?

Hobbs RE.

Cleve Clin J Med. 1998 Nov-Dec;65(10):539-42.

PMID:
9830787
[PubMed - indexed for MEDLINE]
7.

Lisinopril: a review of its use in congestive heart failure.

Simpson K, Jarvis B.

Drugs. 2000 May;59(5):1149-67. Review.

PMID:
10852646
[PubMed - indexed for MEDLINE]
8.

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ.

Lancet. 2000 Aug 19;356(9230):615-20. Erratum in: Lancet 2000 Nov 18;356(9243):1774.

PMID:
10968433
[PubMed - indexed for MEDLINE]
9.

High dose lisinopril in heart failure: economic considerations.

Ess SM, Lüscher TF, Szucs TD.

Cardiovasc Drugs Ther. 2002 Jul;16(4):365-71.

PMID:
12652106
[PubMed - indexed for MEDLINE]
10.

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.

Sculpher MJ, Poole L, Cleland J, Drummond M, Armstrong PW, Horowitz JD, Massie BM, Poole-Wilson PA, Ryden L.

Eur J Heart Fail. 2000 Dec;2(4):447-54.

PMID:
11113723
[PubMed - indexed for MEDLINE]
11.

ACE-inhibitor therapy at relatively high doses and risk of renal worsening in chronic heart failure.

De Vecchis R, Di Biase G, Ariano C, Cioppa C, Giasi A, Ciccarelli A, Pucciarelli A, Cantatrione S.

Arq Bras Cardiol. 2011 Dec;97(6):507-16. Epub 2011 Oct 14. English, Portuguese.

PMID:
22001954
[PubMed - indexed for MEDLINE]
Free Article
12.

ACE inhibitor dosage at the time of listing predicts survival.

Berger R, Kuchling G, Frey B, Kozanly I, Pacher R, Stanek B.

J Heart Lung Transplant. 2000 Feb;19(2):127-33.

PMID:
10703687
[PubMed - indexed for MEDLINE]
13.

The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure.

Levine TB, Levine AB, Keteyian SJ, Narins B.

Clin Cardiol. 1998 Dec;21(12):899-904.

PMID:
9853182
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.

Rydén L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA.

Eur Heart J. 2000 Dec;21(23):1967-78.

PMID:
11071803
[PubMed - indexed for MEDLINE]
Free Article
15.

The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS) trial.

Giles TD, Kerut EK, Roffidal LE, Jones R, Given MB, Hutchinson H, Tresznewsky O.

Blood Press Monit. 2001 Apr;6(2):81-4.

PMID:
11433128
[PubMed - indexed for MEDLINE]
16.

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI.

Lancet. 1997 Mar 15;349(9054):747-52.

PMID:
9074572
[PubMed - indexed for MEDLINE]
17.

Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.

Farquharson CA, Struthers AD.

J Am Coll Cardiol. 2002 Mar 6;39(5):767-75.

PMID:
11869839
[PubMed - indexed for MEDLINE]
18.

Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.

[No authors listed]

Prescrire Int. 2005 Oct;14(79):180-6.

PMID:
16285075
[PubMed - indexed for MEDLINE]
19.

Mode of death in heart failure: findings from the ATLAS trial.

Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Rydén L; Atlas Study Group. Assessment of treatment with lisinopril and survival.

Heart. 2003 Jan;89(1):42-8.

PMID:
12482789
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators.

N Engl J Med. 2001 Dec 6;345(23):1667-75.

PMID:
11759645
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk